The National Agency for Food and Drug Administration and Control (NAFDAC) hereby issue this Public Notice to inform the general public, healthcare institutions, pharmaceutical importers, distributors, and all relevant stakeholders of the blacklisting of NITIN Lifesciences Ltd, an India‑based pharmaceutical manufacturer.

NAFDAC investigations confirmed that ACME Healthcare Limited imported and distributed pharmaceutical products manufactured by NITIN Lifesciences Ltd—including Acmequin (Chloroquine Phosphate Injection 40mg/ml)—under an expired license, constituting a serious violation of Nigerian drug regulatory laws.

NITIN Lifesciences Ltd acted in concert with ACME Healthcare Limited, thereby making the company an accomplice in unlawful pharmaceutical activities within Nigeria.

Accordingly, NAFDAC has imposed the following regulatory actions:

1. Blacklisting of NITIN Lifesciences Ltd

The company is hereby blacklisted from engaging in any pharmaceutical business in Nigeria until further notice.

2. Total Ban on Products

All pharmaceutical products manufactured by NITIN Lifesciences Ltd are prohibited from importation, distribution, and sale within Nigeria.

3. Enforcement and Legal Consequences

Any attempt to violate or circumvent these directives shall attract severe regulatory sanctions, escalated enforcement measures, and international reporting to appropriate regulatory bodies.

All NAFDAC zonal directors and state coordinators have been directed to carry out surveillance and mop up the substandard/falsified products within their zones and states.

NAFDAC implores distributors, suppliers, wholesalers, healthcare providers, and patients to exercise caution and vigilance within the supply chain to avoid distribution, sale, administration, and use of the products. All medical products must be obtained from genuinely authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked. 

If you have any of the products mentioned above, please stop selling or using them immediately and submit your stock to the nearest NAFDAC office. If you or someone you know has used any of these products and experienced adverse reactions or events, we strongly recommend seeking immediate medical advice from a qualified healthcare professional.

Healthcare professionals and consumers are advised to report any suspicion of substandard and falsified medicines to the nearest NAFDAC office, NAFDAC on 0800-162-3322, or via email: sf.alert@nafdac.gov.ng

Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of the medicinal product to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng, or via the Med-safety application available for download on Android and IOS stores, or via e-mail on pharmacovigilance@nafdac.gov.ng  

Thank you.

Prof. Mojisola Christianah Adeyeye FAS
Director General